Abstract Body

Background: HIV-1 has been classified into 4 groups: M, N, O and P. These last years, highly potent broadly neutralizing monoclonal antibodies (bNabs) have been obtained from individuals infected by HIV-1 group M variants. The aim of this study was to analyze the cross-group neutralization potency of these bNabs using a large panel of non-M primary isolates (PI).

Methods: The sensitivity to neutralization of 16 non-M HIV-1 PIs (12 O, 2 N, 1 P, 1 M/O recombinant) was analyzed in a neutralization assay using TZM-bl cells. Twenty two HuMoNabs were used. VRC01, VRC03, 3BNC117 and five clonal variants of NIH45-46G54W target the CD4 binding site (CD4bs). PG9, PG16, PGT145 and PG9-PG16-RH target the N160 glycan-V1V2 site. PGT121, PGT128 and 10-1074 target the N332 glycan-V3 site. 2F5, 4E10 and 10E8 target the MPER of gp41. 8ANC195 target a complex epitope spanning both Env subunits. Two bispecific antibodies that combine the inhibitory activity of an anti-CD4 with that of PG9 or PG16 (BibNabs) were included in the study (PG9-iMab and PG16-iMab).

Results: Cross-group neutralization was observed only with the bNabs targeting the N160 glycan-V1V2 site. Four group O PIs, one group N PI and the group P were neutralized by PG9 and or PG16 at low concentrations (0.04-0.9.39 µg/mL). None of the non-M PIs was neutralized by the bNabs targeting other regions at the highest concentration tested (10 µg/mL), except 10E8 that neutralized weakly two group O PIs (3.35-3.69 µg/mL). The BibNabs neutralized very efficiently all the non-M PIs with IC50 below 1 µg/mL, except two group O strains. The high potency of the BibNabs was mediated by the gp120-binding activity of PG9 and PG16 scFVs.

Conclusions: The N160 glycan-V1V2 site is the most conserved neutralizing site within the four groups of HIV-1. It makes it a potentially interesting target for development of HIV vaccine immunogens. The corresponding bNabs could be useful for immunotherapeutic strategies in patients infected by non-M variants.